|
Nirupama Pike PhD
Sr. Director of Technical Affairs
Thermo Fisher Scientific
Fountain Hills, AZ
USA
|
Rupa serves as the Sr. Director of Technical Affairs for Advanced Therapies. In this role, as the cell
therapy expert, she is responsible for driving new business by supporting the commercial teams and
providing scientific and technical expertise in the CDMO space. She also leads the strategic partnership
initiatives with global BioPharma, Biotech and Healthcare customers to support the advancements of Cell
and Gene Therapies across several Thermo Fisher business units. Prior to this, she served as the Head
of Technical Operations (Patheon part of Thermo Fisher Scientific) where she worked closely with clients
to advance cell-based therapies from early discovery phase to GMP-manufacturing, emphasizing robust
technology transfer and process development and optimization activities. Rupa’s experience spans over
15 years of expertise in GMP manufacturing and she has successfully led GMP operations, process
development and MSAT activities, infrastructure buildout, customer relations and business development.
In her past roles, she has been the Director of Cell Manufacturing for Program for Advanced Cell Therapy
at UW Hospitals and Clinics. At Ligand Pharmaceuticals, she was part of the team that designed novel
hematopoietic screening assays for erythropoietin and thrombopoietin in partnership with
GlaxoSmithKline, a part of the program that led to development of Promacta®, a drug for the treatment
of chronic immune thrombocytopenic purpura. Rupa holds a master’s degree in Biology from Loyola University and a doctorate from Harvard University with focus on Immunology and Hematology.
therapy expert, she is responsible for driving new business by supporting the commercial teams and
providing scientific and technical expertise in the CDMO space. She also leads the strategic partnership
initiatives with global BioPharma, Biotech and Healthcare customers to support the advancements of Cell
and Gene Therapies across several Thermo Fisher business units. Prior to this, she served as the Head
of Technical Operations (Patheon part of Thermo Fisher Scientific) where she worked closely with clients
to advance cell-based therapies from early discovery phase to GMP-manufacturing, emphasizing robust
technology transfer and process development and optimization activities. Rupa’s experience spans over
15 years of expertise in GMP manufacturing and she has successfully led GMP operations, process
development and MSAT activities, infrastructure buildout, customer relations and business development.
In her past roles, she has been the Director of Cell Manufacturing for Program for Advanced Cell Therapy
at UW Hospitals and Clinics. At Ligand Pharmaceuticals, she was part of the team that designed novel
hematopoietic screening assays for erythropoietin and thrombopoietin in partnership with
GlaxoSmithKline, a part of the program that led to development of Promacta®, a drug for the treatment
of chronic immune thrombocytopenic purpura. Rupa holds a master’s degree in Biology from Loyola University and a doctorate from Harvard University with focus on Immunology and Hematology.